Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NOD2/CARD15 does not influence response to infliximab in Crohn's disease.

Gastroenterology - 1 Jul 2002

Vermeire Severine, Louis Edouard, Rutgeerts Paul, De Vos Martine, Van Gossum Andre, Belaiche Jacques, Pescatore Paul, Fiasse Rene, Pelckmans Paul, Vlietinck Robert, Merlin Françoise, Zouali Habib, Thomas Gilles, Colombel Jean-Frederic, Hugot Jean-Pierre

Abstract excerpt

BACKGROUND & AIMS: NOD2/CARD15 was recently identified as the first gene underlying Crohn's disease (CD) susceptibility. Monoclonal antibodies to tumor necrosis factor (TNF)-alpha (infliximab) are a potent treatment for CD, with about 70% of patients responding. It is not clear which factors influence treatment outcome. We assessed whether variants in NOD2/CARD15 are predictive for differences in clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Crohn Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrointestinal Agents

Share to Infliximab

Share to Intracellular Signaling Peptides and Proteins

Share to Nod2 Signaling Adaptor Protein

Share to Reference Values

Share to Tumor Necrosis Factor-alpha

Source

Identifiers

PMID: 12105838
DOI: 10.1053/gast.2002.34172

Genes

NOD2
TNF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NOD2/CARD15 does not influence response to infliximab in Crohn's disease.PMID 12105838Read ↗

Clinical applications of NOD2/CARD15 mutations in Crohn's disease.Semantic proximity Read ↗

NOD2/CARD15 and TNFA, but not IL1B and IL1RN, are associated with Crohn's disease.Semantic proximity Read ↗

Alterations of the CARD15/NOD2 gene and the impact on management and treatment of Crohn's disease patients.Semantic proximity Read ↗

NOD2/CARD15: relevance in clinical practice.Semantic proximity Read ↗

Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials.Semantic proximity Read ↗

Lessons to be learned from the NOD2 gene in Crohn's disease.Semantic proximity Read ↗

Detailed assessment of NOD2/CARD15 exonic variation in inflammatory bowel disease in Scotland: implications for disease pathogenesis.Semantic proximity Read ↗

NOD2/CARD15 gene mutation is not associated with susceptibility to Wegener's granulomatosis.Semantic proximity Read ↗

Analysis of CARD15/NOD2 haplotypes fails to identify common variants associated with rheumatoid arthritis susceptibility.Semantic proximity Read ↗

NOD2/CARD15 gene polymorphisms are not associated with collagenous colitis.Semantic proximity Read ↗

NOD2/CARD15 gene polymorphisms in Crohn's disease: a genotype- phenotype analysis.Semantic proximity Read ↗

CARD15/NOD2 mutations in Crohn's disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.